NCT07046559View on ClinicalTrials.gov

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
HealthyCancer
Interventions
DRUG

LY4066708

Administered IV

DRUG

Placebo

Administered IV

DRUG

LY4066708

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

LS11 9EH

RECRUITING

Fortrea Clinical Research Unit, Holbeck, Leeds

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY